Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation

PURPOSE: To investigate the safety and efficacy of dabrafenib and trametinib combination therapy for BRAF V600 mutation-positive unresectable and metastatic melanoma in over 100 Japanese patients of a real-world clinical setting. PATIENTS: The surveillance period of interim post-marketing surveillan...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int J Clin Oncol
Main Authors: Teshima, Yasutomo, Kizaki, Minako, Kurihara, Ryohei, Kano, Ryosuke, Harumiya, Miki
Formato: Artigo
Idioma:Inglês
Publicado: Springer Singapore 2020
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7498495/
https://ncbi.nlm.nih.gov/pubmed/32699976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-020-01737-3
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares